{"id":"zoledronate","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute nephropathy","Anuria","Aseptic necrosis of bone of jaw","Bone pain","Breastfeeding (mother)","Chronic heart failure","Dehydration","Fracture of femur","Fragile capillaries","Hyperkalemia","Hypernatremia","Hypocalcemia","Hypomagnesemia","Hyponatremia","Hypoparathyroidism","Hypophosphatemia","Hypovolemia","Impaired renal function disorder","Intracranial hemorrhage","Invasive Dental Procedure","Joint pain","Malabsorption States","Muscle pain","Oliguria","Pregnancy, function","Pulmonary congestion","Severe dehydration","Severe renal impairment","Small intestine excision","Thyroid Surgery","Tooth disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL4746555","moleculeType":"Unknown","molecularWeight":"360.02"},"aliases":["zoledronic acid; zolendronate","Zoledronic acid","zoledronic acid","Zometa","Zoledronic acid intravenous once a year"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase"},"_scrapedAt":"2026-03-28T00:16:41.898Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Bone Metastases of Solid Tumors","diseaseId":"bone-metastases-of-solid-tumors","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Glucocorticoid Induced Osteoporosis","diseaseId":"glucocorticoid-induced-osteoporosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Humoral hypercalcemia of malignancy","diseaseId":"humoral-hypercalcemia-of-malignancy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hypogonadal Osteoporosis in Males","diseaseId":"hypogonadal-osteoporosis-in-males","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Osteitis deformans","diseaseId":"osteitis-deformans","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Osteolytic Lesions of Multiple Myeloma","diseaseId":"osteolytic-lesions-of-multiple-myeloma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Osteoporosis","diseaseId":"osteoporosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Postmenopausal osteoporosis","diseaseId":"postmenopausal-osteoporosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Glucocorticoid-Induced Osteoporosis","diseaseId":"prevention-of-glucocorticoid-induced-osteoporosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06533865","phase":"PHASE3","title":"Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-03-19","conditions":"FHA (Functional Hypothalamic Amenorrhea)","enrollment":114},{"nctId":"NCT07471516","phase":"PHASE1, PHASE2","title":"Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-25","conditions":"Congenital Dyserythropoietic Anemia (CDA)","enrollment":2},{"nctId":"NCT06625190","phase":"PHASE1, PHASE2","title":"Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-02-11","conditions":"Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma","enrollment":27},{"nctId":"NCT04608630","phase":"PHASE2","title":"Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults","status":"RECRUITING","sponsor":"Australian and New Zealand Intensive Care Research Centre","startDate":"2021-07-15","conditions":"Critical Illness, Osteoporosis","enrollment":450},{"nctId":"NCT03859895","phase":"","title":"Zoledronate In the Prevention of Paget's Disease: Long Term Extension","status":"ENROLLING_BY_INVITATION","sponsor":"University of Edinburgh","startDate":"2019-04-05","conditions":"Paget Disease","enrollment":287},{"nctId":"NCT05058976","phase":"PHASE4","title":"Romosozumab Use to Build Skeletal Integrity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Susan L. Greenspan","startDate":"2021-09-15","conditions":"Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture","enrollment":184},{"nctId":"NCT06811363","phase":"","title":"Contribution of Bone to Urine Citrate","status":"ENROLLING_BY_INVITATION","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02-28","conditions":"Osteoporosis","enrollment":25},{"nctId":"NCT07406685","phase":"PHASE4","title":"The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-03-17","conditions":"Postmenopausal Osteoporosis, Postmenopausal Osteopenia, Primary Osteoporosis","enrollment":52},{"nctId":"NCT06118905","phase":"PHASE4","title":"Preserving Geriatric Muscle With an Osteoporosis Medication","status":"RECRUITING","sponsor":"Susan L. Greenspan","startDate":"2024-02-08","conditions":"Osteoporosis","enrollment":155},{"nctId":"NCT04253340","phase":"NA","title":"Study of a Bone Assessment Technique, Bone Mineral Analyser, Concerning the Prediction of Improvement in Bone Status After an Infusion of Zoledronic Acid in Osteoporotic Women","status":"WITHDRAWN","sponsor":"University Hospital, Rouen","startDate":"2020-03-01","conditions":"Osteoporosis","enrollment":""},{"nctId":"NCT03664687","phase":"PHASE4","title":"Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2018-10-31","conditions":"Early-stage Breast Cancer","enrollment":211},{"nctId":"NCT06374459","phase":"PHASE1, PHASE2","title":"Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-01-30","conditions":"Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer","enrollment":152},{"nctId":"NCT07375290","phase":"PHASE1","title":"Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2026-02","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":20},{"nctId":"NCT06135298","phase":"PHASE4","title":"FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA","status":"COMPLETED","sponsor":"Aksaray University","startDate":"2023-12-01","conditions":"Trochanteric Fracture of Femur, Osteoporotic Fracture of Femur, Hip Fractures","enrollment":20},{"nctId":"NCT05666310","phase":"PHASE4","title":"Muscle Impact of Treating Osteoporosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nami Safai Haeri","startDate":"2023-02-14","conditions":"Sarcopenia, Osteoporosis","enrollment":20},{"nctId":"NCT06767150","phase":"PHASE4","title":"StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2025-10-02","conditions":"Postmenopausal Osteoporosis","enrollment":200},{"nctId":"NCT05400603","phase":"PHASE1","title":"Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-11-06","conditions":"Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma","enrollment":24},{"nctId":"NCT04779216","phase":"PHASE3","title":"Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa","status":"COMPLETED","sponsor":"Karen Klahr Miller, MD","startDate":"2021-09-20","conditions":"Bone Density, Low, Bone Loss, Anorexia Nervosa","enrollment":30},{"nctId":"NCT07281586","phase":"PHASE4","title":"Step-down Therapy After Long-term Osteoporosis Treatment","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-01-01","conditions":"Osteoporosis","enrollment":44},{"nctId":"NCT02325414","phase":"PHASE2","title":"Prevention of Bone Loss After Acute SCI by Zoledronic Acid","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-02","conditions":"Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss","enrollment":60},{"nctId":"NCT05204836","phase":"PHASE1","title":"Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury","status":"TERMINATED","sponsor":"University of Calgary","startDate":"2023-05-16","conditions":"Anterior Cruciate Ligament Tear, Anterior Cruciate Ligament Rupture, Anterior Cruciate Ligament Injuries","enrollment":4},{"nctId":"NCT04549207","phase":"PHASE4","title":"Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2020-10-09","conditions":"Breast Cancer, Castration-resistant Prostate Cancer","enrollment":240},{"nctId":"NCT06759064","phase":"PHASE1, PHASE2","title":"Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-09-12","conditions":"Cancer of Stomach, Adenocarcinoma, Ascites, Malignant","enrollment":24},{"nctId":"NCT05091099","phase":"PHASE4","title":"The Optimal Sequential Therapy After Long Term Denosumab Treatment","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2022-01-10","conditions":"Osteoporosis","enrollment":44},{"nctId":"NCT03173976","phase":"PHASE1","title":"Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mohammed Milhem","startDate":"2017-07-18","conditions":"Chondrosarcoma","enrollment":17},{"nctId":"NCT04087096","phase":"PHASE4","title":"Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-08-24","conditions":"Bariatric Surgery Candidate, Bone Loss","enrollment":36},{"nctId":"NCT02508038","phase":"PHASE1","title":"Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2016-02-12","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma","enrollment":22},{"nctId":"NCT03295981","phase":"PHASE3","title":"Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone","status":"RECRUITING","sponsor":"St. Louis University","startDate":"2018-05-03","conditions":"Giant Cell Tumor of Bone","enrollment":120},{"nctId":"NCT05053750","phase":"EARLY_PHASE1","title":"TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-12-14","conditions":"Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer","enrollment":14},{"nctId":"NCT07204496","phase":"","title":"A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2025-09-26","conditions":"Advanced Bladder Cancer","enrollment":20},{"nctId":"NCT05655013","phase":"PHASE4","title":"Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2023-05-10","conditions":"Osteoporosis, Postmenopausal","enrollment":200},{"nctId":"NCT06762730","phase":"PHASE4","title":"Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals","status":"RECRUITING","sponsor":"Hadassah Medical Organization","startDate":"2024-12-09","conditions":"HIV Infected Individuals, Osteopenia","enrollment":110},{"nctId":"NCT03735537","phase":"PHASE4","title":"Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2016-11-01","conditions":"Osteogenesis Imperfecta","enrollment":350},{"nctId":"NCT05080790","phase":"PHASE2","title":"Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2021-11-15","conditions":"Leiomyosarcoma","enrollment":7},{"nctId":"NCT06876636","phase":"NA","title":"Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-03-10","conditions":"Breast Cancer Metastatic","enrollment":99},{"nctId":"NCT06513624","phase":"PHASE1","title":"ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2024-12-09","conditions":"With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer","enrollment":16},{"nctId":"NCT07056478","phase":"PHASE3","title":"RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients","status":"NOT_YET_RECRUITING","sponsor":"Prince of Wales Hospital, Shatin, Hong Kong","startDate":"2026-01-01","conditions":"Sarcopenia in Elderly","enrollment":130},{"nctId":"NCT07043608","phase":"PHASE2","title":"Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases","status":"NOT_YET_RECRUITING","sponsor":"Kelly Fitzgerald, MD","startDate":"2025-09-30","conditions":"Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic","enrollment":20},{"nctId":"NCT00470223","phase":"PHASE3","title":"Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2007-03","conditions":"Sarcoma","enrollment":318},{"nctId":"NCT02517918","phase":"PHASE1","title":"Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2015-02","conditions":"Solid Tumor, Osteosarcoma","enrollment":23},{"nctId":"NCT03073785","phase":"PHASE2","title":"Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nebraska","startDate":"2016-09-16","conditions":"Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7","enrollment":46},{"nctId":"NCT05091086","phase":"PHASE4","title":"The Optimal Long Term Treatment Strategy of Anti-resorptive Medications","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-11-20","conditions":"Osteoporosis, Bone Mineral Density","enrollment":60},{"nctId":"NCT03958565","phase":"","title":"Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-04-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":100},{"nctId":"NCT06164795","phase":"","title":"Sequential Therapies After Osteoanabolic Treatment","status":"RECRUITING","sponsor":"424 General Military Hospital","startDate":"2023-11-25","conditions":"Osteoporosis, Postmenopausal","enrollment":150},{"nctId":"NCT05575167","phase":"","title":"Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)","status":"RECRUITING","sponsor":"424 General Military Hospital","startDate":"2023-11-28","conditions":"Osteoporosis, Postmenopausal","enrollment":125},{"nctId":"NCT06859580","phase":"PHASE4","title":"Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2025-03-01","conditions":"Primary Hyperparathyroidism","enrollment":140},{"nctId":"NCT05361408","phase":"PHASE4","title":"A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis (ZOOM Study)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2022-02-11","conditions":"Osteoporosis","enrollment":114},{"nctId":"NCT03924414","phase":"PHASE4","title":"Trial of Parkinson's And Zoledronic Acid","status":"ACTIVE_NOT_RECRUITING","sponsor":"California Pacific Medical Center Research Institute","startDate":"2019-11-15","conditions":"Parkinson Disease, Osteoporosis, Parkinsonism","enrollment":2650},{"nctId":"NCT05328154","phase":"PHASE2","title":"MAGnesium Effect With ANtiosteoporotic Drugs","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2022-06-28","conditions":"Osteoporosis, Postmenopausal","enrollment":45},{"nctId":"NCT04177940","phase":"PHASE4","title":"Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-17","conditions":"Osteoporosis","enrollment":45},{"nctId":"NCT05906056","phase":"NA","title":"Continuous Passive Motion Versus Heterotopic Ossification","status":"RECRUITING","sponsor":"University of Ioannina","startDate":"2023-05-12","conditions":"Traumatic Brain Injury, Spinal Cord Injuries, Stroke","enrollment":20},{"nctId":"NCT01671774","phase":"PHASE1","title":"Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-10-16","conditions":"CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus","enrollment":29},{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":"Osteoporosis","enrollment":517991},{"nctId":"NCT05614778","phase":"","title":"Study to Investigate the Efficacy and Safety After Administration of Daewoong Zoledronic Acid for the Purpose of Treatment or Prevention of Osteoporosis","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-02-28","conditions":"Osteoporosis","enrollment":2881},{"nctId":"NCT06643780","phase":"PHASE4","title":"RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis","status":"RECRUITING","sponsor":"Prince of Wales Hospital, Shatin, Hong Kong","startDate":"2024-04-09","conditions":"Sarcopenia in Elderly","enrollment":120},{"nctId":"NCT06621069","phase":"","title":"The Effect of Long-term Use of Bisphosphonates on Femur Morphology","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-06-01","conditions":"Osteoporosis, Knee Osteoarthristis","enrollment":140},{"nctId":"NCT04279392","phase":"PHASE1, PHASE2","title":"Healthy Body, Healthy Bones After Bariatric Surgery Trial","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2020-09-01","conditions":"Bariatric Surgery Candidate, Bone Loss, Bone Resorption","enrollment":10},{"nctId":"NCT00365105","phase":"PHASE3","title":"Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2006-07-11","conditions":"Breast Cancer, Lung Cancer, Metastatic Cancer","enrollment":261},{"nctId":"NCT01348269","phase":"PHASE3","title":"Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome","status":"COMPLETED","sponsor":"Wuerzburg University Hospital","startDate":"2011-05","conditions":"Bone Marrow Edema","enrollment":48},{"nctId":"NCT03336983","phase":"PHASE2","title":"Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2017-12-01","conditions":"Prostate Cancer, Bone Metastases","enrollment":126},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT05405894","phase":"","title":"Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2022-09-01","conditions":"Osteoporosis, Osteoporosis, Postmenopausal, Osteopenia","enrollment":20},{"nctId":"NCT03396315","phase":"PHASE2","title":"Bisphosphonates for Prevention of Post-Denosumab Bone Loss","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-01-29","conditions":"IOP, Osteoporosis","enrollment":24},{"nctId":"NCT03868033","phase":"PHASE4","title":"Denosumab Sequential Therapy","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-04-12","conditions":"Osteoporosis","enrollment":101},{"nctId":"NCT00733538","phase":"PHASE4","title":"Stage I Multiple Myeloma Treatment","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2004-12","conditions":"Multiple Myeloma","enrollment":89},{"nctId":"NCT04304755","phase":"PHASE2","title":"Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2021-10-25","conditions":"Neovascular Age-related Macular Degeneration","enrollment":40},{"nctId":"NCT05025293","phase":"PHASE4","title":"Zoledronate Early to Hip Fracture Patients - Safe and Effective?","status":"RECRUITING","sponsor":"Lene Bergendal Solberg","startDate":"2021-12-15","conditions":"Hip Fractures, Osteoporosis","enrollment":300},{"nctId":"NCT05677152","phase":"PHASE2","title":"Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder","status":"RECRUITING","sponsor":"AUVA Traumazentrum Vienna Site UKH Meidling","startDate":"2022-08-22","conditions":"Orthopedics, Traumatology","enrollment":80},{"nctId":"NCT00295646","phase":"PHASE3","title":"Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"1999-06","conditions":"Breast Cancer","enrollment":1803},{"nctId":"NCT05743179","phase":"PHASE4","title":"The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-12-05","conditions":"Hip Fractures, Pneumonia","enrollment":2692},{"nctId":"NCT05904353","phase":"NA","title":"A Study to Improve the Collaboration Between Primary and Secondary Health Care on the Treatment of Osteoporosis After a Hip Fracture.","status":"RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2024-01-01","conditions":"Hip Fractures, Osteoporosis, Zoledronic Acid","enrollment":200},{"nctId":"NCT04498715","phase":"NA","title":"Trochanteric Femur Fracture Operated With Dynamic Hip Screw System (DHS) Augmented With a Biphasic Apatite Sulphate Combined With Systemic or Local Bisphosphonate","status":"UNKNOWN","sponsor":"Lithuanian University of Health Sciences","startDate":"2021-06-01","conditions":"Trochanteric Fracture of Femur","enrollment":20},{"nctId":"NCT06221072","phase":"PHASE3","title":"A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-04-05","conditions":"Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors","enrollment":1360},{"nctId":"NCT03930992","phase":"PHASE3","title":"Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2019-04-17","conditions":"Secondary Osteoporosis","enrollment":30},{"nctId":"NCT00525759","phase":"PHASE2","title":"Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-07","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT06059222","phase":"PHASE4","title":"The Optimised Use of Romozosumab Study","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2023-10-02","conditions":"Osteoporosis","enrollment":270},{"nctId":"NCT03358017","phase":"PHASE2","title":"Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-05","conditions":"Triple Negative Breast Cancer","enrollment":54},{"nctId":"NCT03862833","phase":"PHASE1","title":"Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2019-05-07","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":30},{"nctId":"NCT00580047","phase":"NA","title":"Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2003-12-01","conditions":"Renal Insufficiency","enrollment":59},{"nctId":"NCT02589600","phase":"PHASE4","title":"Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)","status":"COMPLETED","sponsor":"Susan L. Greenspan","startDate":"2016-01","conditions":"Osteoporotic Fractures, Osteoporosis, Postmenopausal","enrollment":310},{"nctId":"NCT06051344","phase":"PHASE4","title":"Effect of Zoledronic Acid in Primary Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Toufiqe-E-Ealahi","startDate":"2023-01-01","conditions":"Primary Osteoarthritis","enrollment":92},{"nctId":"NCT06023420","phase":"PHASE1, PHASE2","title":"Efficacy of a Herbal Formula for Bone Metastases","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2024-02-01","conditions":"Bone Metastases","enrollment":36},{"nctId":"NCT00172029","phase":"PHASE4","title":"Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-04","conditions":"Breast Cancer With Metastatic Bone Disease","enrollment":116},{"nctId":"NCT04736693","phase":"","title":"Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-22","conditions":"Osteoporosis","enrollment":18028},{"nctId":"NCT00556374","phase":"PHASE3","title":"Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12-18","conditions":"Breast Cancer","enrollment":3420},{"nctId":"NCT03118570","phase":"PHASE2","title":"A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2017-09-11","conditions":"Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV","enrollment":112},{"nctId":"NCT01967160","phase":"","title":"Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-01-02","conditions":"Osteonecrosis of the Jaw, Infection Leading to Hospitalization","enrollment":2560},{"nctId":"NCT01642901","phase":"PHASE3","title":"Zoledronic Acid in Acute Spinal Cord Injury","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2012-09","conditions":"Spinal Cord Injury","enrollment":16},{"nctId":"NCT05866172","phase":"PHASE3","title":"HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-05-10","conditions":"Hepatocellular Carcinoma","enrollment":264},{"nctId":"NCT00268476","phase":"PHASE2, PHASE3","title":"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical Research Council","startDate":"2005-07-08","conditions":"Prostate Cancer","enrollment":11992},{"nctId":"NCT00885326","phase":"PHASE1","title":"N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2009-12","conditions":"Neuroblastoma","enrollment":29},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":"Osteoporosis, Osteoporosis Fracture, Drug Therapy","enrollment":216155},{"nctId":"NCT00412022","phase":"PHASE3","title":"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2004-03","conditions":"Breast Cancer","enrollment":1294},{"nctId":"NCT05595603","phase":"PHASE2","title":"Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03","conditions":"Giant Cell Tumor of Bone","enrollment":153},{"nctId":"NCT00916747","phase":"PHASE2","title":"Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2009-08","conditions":"Progeria","enrollment":85},{"nctId":"NCT05106517","phase":"PHASE2, PHASE3","title":"Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2021-09-08","conditions":"Denosumab vs Zoledronate","enrollment":122},{"nctId":"NCT05638399","phase":"PHASE3","title":"Denosumab vs Zoledronate After Lumbar Fusion","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2020-01-15","conditions":"Osteopenia, Lumbar Spondylolisthesis","enrollment":100},{"nctId":"NCT02286830","phase":"PHASE4","title":"Prolonged Protection From Bone Disease in Multiple Myeloma","status":"COMPLETED","sponsor":"Thomas Lund","startDate":"2015-01","conditions":"Multiple Myeloma","enrollment":158},{"nctId":"NCT05598606","phase":"PHASE4","title":"Denosumab vs Zoledronate After Vertebroplasty","status":"COMPLETED","sponsor":"Shenzhen People's Hospital","startDate":"2021-01-12","conditions":"Denosumab Allergy, Zoledronic Acid Allergy","enrollment":75},{"nctId":"NCT01875458","phase":"","title":"Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-04-13","conditions":"Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture","enrollment":314}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1956,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Zoledronate","genericName":"Zoledronate","companyName":"Children's Hospital Medical Center, Cincinnati","companyId":"children-s-hospital-medical-center-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":14,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}